Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Genix Pharmaceuticals Corp., CA37232A1093

Genix Pharmaceuticals Corp., CA37232A1093

14.01.2020 - 20:44:51

Genix Acquires Exclusive Rights to SUCANON and RENOCHLOR

DGAP-News: Genix Pharmaceuticals Corp.

/ Key word(s): Miscellaneous

Genix Acquires Exclusive Rights to SUCANON(R) and RENOCHLOR(R)

14.01.2020 / 20:42

The issuer is solely responsible for the content of this announcement.

14.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Genix Pharmaceuticals Corp.

Canada ISIN: CA37232A1093 EQS News ID: 953583   End of News DGAP News Service

953583  14.01.2020 

@ dgap.de